Abuse-Deterrent Exemption From Medicaid Rebates Hinges On FDA Standards
Opioid formulations with abuse-deterrent properties will be exempt from Medicaid price-inflation rebates if they meet FDA standards, Centers for Medicare and Medicaid Services says in guidance to manufacturers.
You may also be interested in...
CMS issues interim final rule to ensure there’s ‘no confusion’ that line extensions are now subject to higher Medicaid rebate requirements.
Comprehensive opioid addiction legislation is considered by House-Senate conference committee on July 6.
Manufacturers must continue to use their discretion on which line extensions should be subject to inflation-based Medicaid rebates in lieu of guidance from CMS in its recent AMP final rule.